Researchers should also compare well-established PAH therapies to agents targeting the ACE2/Ang-(1-7)/Mas 1 receptor signaling in order to appreciate the latter’s potential non-inferiority. This evidence concerns the gene ACE2 and pulmonary arterial hypertension.